What is Micardis?
Micardis is an angiotensin II receptor blocker (ARB) used for the treatment of hypertension or high blood pressure. It works by blocking the binding of angiotensin II to angiotensin II type 1 (AT1) receptors in the blood vessels, kidneys and adrenal glands. This helps relax the blood vessels which decreases blood pressure and increases urine output. Micardis was first approved in 1998 and is sold under the brand name Micardis by Boehringer Ingelheim.
How Does it Work?
The renin-angiotensin-aldosterone system (RAAS) plays a key role in regulating blood pressure and fluid balance in the body. Angiotensin II is a hormone produced by this system which causes arteries to constrict and increases blood pressure. It also stimulates the release of aldosterone from the adrenal glands which increases sodium and water retention by the kidneys.
Micardis works by selectively blocking the binding of angiotensin II to AT1 receptors located mainly in the blood vessels, heart, adrenal glands and kidneys. Telmisartan pressure raising effects of angiotensin II such as vasoconstriction and sodium retention. By decreasing peripheral vascular resistance and volume overload, Micardis lowers blood pressure levels. It allows increased renal blood flow and sodium excretion which also helps control hypertension.
Clinical Studies on Efficacy
Numerous clinical trials have demonstrated the efficacy of Telmisartan in reducing both systolic and diastolic blood pressure. A meta-analysis published in 2007 analyzed data from nine randomized controlled trials with a total of 4,305 patients. It found Micardis to be more effective than other ARBs like valsartan, losartan and irbesartan in reducing both types of blood pressure after 8-12 weeks of treatment.
The ONgoing Micardis Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET) study compared Micardis to the ACE inhibitor ramipril and a combination of both drugs for cardiovascular protection. Over 25,000 patients with vascular disease or highrisk diabetes were followed for a median of 56 months. Micardis was found to be as effective as ramipril in reducing major cardiovascular events and death rates.
Micardis has also shown benefits in preventing new-onset diabetes. Post-hoc analysis of the ONTARGET data revealed a 14% reduced risk of new-onset diabetes with Micardis versus ramipril alone after 4.5 years. The prospective Micardis Randomized AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) trial of 5,969 patients also saw a similar 25% reduced risk of new-onset diabetes with Micardis.
Side Effects and Precautions
Micardis is generally well-tolerated with a safety profile similar to other ARBs. Common side effects reported in clinical trials included dizziness, upper respiratory infection, back pain and diarrhea. Rare but serious side effects can include hyperkalemia (high potassium levels), angioedema (swelling of face, lips, tongue), renal failure and hypotension (low blood pressure).
Precautions need to be taken in patients with impaired kidney or liver function. Close monitoring of kidney function tests is advised especially in those with pre-existing renal artery stenosis. Telmisartan should be used cautiously or avoided in pregnancy as fetal toxicity was noted in animal studies. Interactions may occur when taken with potassium supplements, NSAIDs or diuretics which can raise potassium levels. Overall, Micardis has a favorable benefit-risk profile for hypertension management.
Dosage and Administration
The recommended starting dose of Micardis is 40 mg once daily which can be increased up to 80 mg based on blood pressure response. It can be taken with or without food and should ideally be administered at the same time each day with consistent timing. For better adherence, fixed-dose combination pills of Micardis with diuretics like hydrochlorothiazide are available for patients not at their blood pressure goal on a single agent. Micardis provides effective 24-hour control of blood pressure with convenient once-daily dosing.
Telmisartan is an effective antihypertensive from the ARB class which lowers blood pressure by selectively blocking angiotensin II receptors. Numerous clinical studies support its role as monotherapy or in combination with other agents for hypertension management. The advantages of Micardis include a favorable safety profile, convenience of once-daily dosing and additional benefits like reduction in cardiovascular events and newonset diabetes. With appropriate dosage adjustments, Micardis is generally well-tolerated and provides consistent blood pressure control for treating hypertension.
Get this Report in Japanese Language
Get this Reports in Korean Language
About Author:
Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.
(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/ )